Gsa Capital Partners LLP Corbus Pharmaceuticals Holdings, Inc. Transaction History

Gsa Capital Partners LLP

11 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2022 Aug 09, 2022	SELL	$0.21 - $0.53 $108,739 - $274,437	-517,806 Closed	0 $0
Q1 2022 May 11, 2022	BUY	$0.32 - $0.67 $165,697 - $346,930	517,806 New	517,806 $275,000
Q1 2020 May 12, 2020	SELL	$3.44 - $7.21 $197,758 - $414,488	-57,488 Closed	0 $0
Q4 2019 Feb 12, 2020	BUY	$4.29 - $5.64 $179,090 - $235,447	41,746 Added 265.19%	57,488 $314,000
Q3 2019 Nov 12, 2019	BUY	$4.87 - $7.08 $76,663 - $111,453	15,742 New	15,742 $77,000
Q4 2018 Feb 12, 2019	SELL	$5.26 - $7.97 $89,946 - $136,287	-17,100 Closed	0 $0
Q3 2018 Nov 13, 2018	SELL	$4.65 - $7.95 $569,160 - $973,080	-122,400 Reduced 87.74%	17,100 $129,000
Q2 2018 Aug 09, 2018	BUY	$5.05 - $6.8 $704,475 - $948,600	139,500 New	139,500 $704,000
Q1 2018 May 11, 2018	SELL	$5.6 - $9.25 $372,400 - $615,125	-66,500 Closed	0 $0
Q4 2017 Feb 14, 2018	SELL	$6.6 - $7.78 $226,380 - $266,854	-34,300 Reduced 34.03%	66,500 $472,000
Q3 2017 Nov 20, 2017	BUY	$5.75 - $7.75 $579,600 - $781,200	100,800	100,800 $721,000

38.7K

Ticker CRBP
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 125,268,000
Market Cap $2.26B
Description
Corbus Pharmaceuticals Holdings, Inc., a biopharmaceutical company, focuses on the development of immune modulators for immuno-oncology and fibrosis diseases. It develops lenabasum, an oral molecule that selectively activates cannabinoid receptor type 2 (CB2), which is in Phase II clinical trial to treat systemic lupus erythematosus; CRB-601, an...

Get notified when there are updates to the investment portfolio of Gsa Capital Partners LLP, based on Form 13F filings with the SEC.

Stay updated on Gsa Capital Partners LLP with notifications on news.